Article thumbnail

Local therapy of cancer with free IL-2

By Willem Den Otter, John J. L. Jacobs, Jan J. Battermann, Gerrit Jan Hordijk, Zachary Krastev, Ekaterina V. Moiseeva, Rachel J. E. Stewart, Paul G. P. M. Ziekman and Jan Willem Koten

Abstract

This is a position paper about the therapeutic effects of locally applied free IL-2 in the treatment of cancer. Local therapy: IL-2 therapy of cancer was originally introduced as a systemic therapy. This therapy led to about 20% objective responses. Systemic therapy however was very toxic due to the vascular leakage syndrome. Nevertheless, this treatment was a break-through in cancer immunotherapy and stimulated some interesting questions: Supposing that the mechanism of IL-2 treatment is both proliferation and tumoricidal activity of the tumor infiltrating cells, then locally applied IL-2 should result in a much higher local IL-2 concentration than systemic IL-2 application. Consequently a greater beneficial effect could be expected after local IL-2 application (peritumoral = juxtatumoral, intratumoral, intra-arterial, intracavitary, or intratracheal = inhalation). Free IL-2: Many groups have tried to prepare a more effective IL-2 formulation than free IL-2. Examples are slow release systems, insertion of the IL-2 gene into a tumor cell causing prolonged IL-2 release. However, logistically free IL-2 is much easier to apply; hence we concentrated in this review and in most of our experiments on the use of free IL-2. Local therapy with free IL-2 may be effective against transplanted tumors in experimental animals, and against various spontaneous carcinomas, sarcomas, and melanoma in veterinary and human cancer patients. It may induce rejection of very large, metastasized tumor loads, for instance advanced clinical tumors. The effects of even a single IL-2 application may be impressive. Not each tumor or tumor type is sensitive to local IL-2 application. For instance transplanted EL4 lymphoma or TLX9 lymphoma were not sensitive in our hands. Also the extent of sensitivity differs: In Bovine Ocular Squamous Cell Carcinoma (BOSCC) often a complete regression is obtained, whereas with the Bovine Vulval Papilloma and Carcinoma Complex (BVPCC) mainly stable disease is attained. Analysis of the results of local IL-2 therapy in 288 cases of cancer in human patients shows that there were 27% Complete Regressions (CR), 23% Partial Regressions (PR), 18% Stable Disease (SD), and 32% Progressive Disease (PD). In all tumors analyzed, local IL-2 therapy was more effective than systemic IL-2 treatment. Intratumoral IL-2 applications are more effective than peritumoral application or application at a distant site. Tumor regression induced by intratumoral IL-2 application may be a fast process (requiring about a week) in the case of a highly vascular tumor since IL-2 induces vascular leakage/edema and consequently massive tumor necrosis. The latter then stimulates an immune response. In less vascular tumors or less vascular tumor sites, regression may require 9–20 months; this regression is mainly caused by a cytotoxic leukocyte reaction. Hence the disadvantageous vascular leakage syndrome complicating systemic treatment is however advantageous in local treatment, since local edema may initiate tumor necrosis. Thus the therapeutic effect of local IL-2 treatment is not primarily based on tumor immunity, but tumor immunity seems to be useful as a secondary component of the IL-2 induced local processes. If local IL-2 is combined with surgery, radiotherapy or local chemotherapy the therapeutic effect is usually greater than with either therapy alone. Hence local free IL-2 application can be recommended as an addition to standard treatment protocols. Local treatment with free IL-2 is straightforward and can readily be applied even during surgical interventions. Local IL-2 treatment is usually without serious side effects and besides minor complaints it is generally well supported. Only small quantities of IL-2 are required. Hence the therapy is relatively cheap. A single IL-2 application of 4.5 million U IL-2 costs about 70 Euros. Thus combined local treatment may offer an alternative in those circumstances when more expensive forms of treatment are not available, for instance in resource poor countries

Topics: Position Paper
Publisher: Springer-Verlag
OAI identifier: oai:pubmedcentral.nih.gov:2335290
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2001). A mesothelioma that is sensitive to locally applied IL-2. Cancer Immunol Immunother 50:226–227
  2. (1995). A phase I study of intravesical continuous perfusion of recombinant interleukin-2 in patients with superWcial bladder cancer.
  3. (1981). Analysis of T cell function in autoimmune murine strains. Defects in production and responsiveness to interleukin 2.
  4. (1989). Anti-tumor eVect of interleukin-2 and interleukin-1 in mice transplanted with diVerent syngeneic tumors.
  5. (1997). Anti-tumor eVects of local irradiation in combination with peritumoral administration of low doses of recombinant interleukin-2 (rIL-2). Radiat Oncol Investig 5:54–61
  6. (1994). Antitumor eVect of locally injected low doses of recombinant human interleukin2 in bovine vulval papilloma and carcinoma. Vet Immunol Immunopathol 41:19–29
  7. (1990). Antitumour eVect of intratumoral injection of human recombinant interleukin-2 in patients with hepatocellular carcinoma: a preliminary report.
  8. (2006). Changes in cytokine proWle during local IL-2 therapy in cancer patients.
  9. (2003). Chemoimmunotherapy in mice carrying HPV16-associated, MHC class I+ and class I- tumours: EVects of CBM-4A potentiated with IL-2, IL-12, GM-CSF and genetically modiWed tumour vaccines.
  10. (2003). Comparison of the local treatment of equine sarcoids with IL-2 or cisplatin/IL-2. Cancer Immunol Immunother 52:179–184
  11. (2004). Complete remission of cutaneous satellite and in-transit metastases.
  12. (1984). Drug targeting in cancer therapy. In: Senior J, Trouet A (eds), Receptor-mediated targeting of drugs.
  13. (1999). EVect of local interleukin-2 treatment on spontaneous tumours of diVerent immunogenic strength.
  14. (2000). EVect of perilesional injections of PEG-interleukin-2 on basal cell carcinoma. Dermatol Surg 26:1037–1040
  15. (1986). EVect of recombinant IL-2 (R-IL-2) on in vivo growth of murine myeloma X5563. Cancer Immunol Immunother 23:25–
  16. (1999). EVective cancer therapy with a single injection of interleukin-2 at the site of the tumour.
  17. (1986). Extravasation of intravascular Xuid mediated by the systemic administration of recombinant interleukin 2.
  18. (2004). Further development of local IL-2 therapy of cancer: multiple versus single IL-2 treatment of transplanted murine colon carcinoma.
  19. (1999). Gabizon A
  20. (1983). Growth inhibition of an MC-induced mouse sarcoma by TCGF (IL-2) containing preparations.
  21. (1997). Herberman RB
  22. (2000). High dose inhalation interleukin 2 therapy for lung metastases in patients with malignant melanoma.
  23. (2003). IL-2 loaded dextran microspheres with attractive histocompatibility properties for local IL-2 cancer therapy.
  24. (2004). IL-2 regulatory T cells, and tolerance.
  25. (1989). Immunotherapy of mice with a large burden of disseminated lymphoma with low-dose interleukin-2. Cancer Res 49:7037–7040950 Cancer Immunol Immunother
  26. (1990). Increased local antitumor eVects of interleukin 2 liposomes in mice with MCA-106 sarcoma pulmonary metastases.
  27. (1997). Inhaled interleukin-2 therapy in pulmonary metastatic renal cell carcinoma.
  28. (1999). Interleukin-2 (IL-2) therapy: potential advantages of locoregional versus systemic administration. Cancer Treatment Rev
  29. (2006). Interleukin-2 for the treatment of solid tumors other than melanoma and renal cell carcinoma.
  30. (2000). Interleukin-2 in the treatment of renal cancer.
  31. (2002). Interleukin-2 inhibits proliferation of HPV-associated tumor cells and halts tumor growth in vivo.
  32. (1998). Interleukin-2: Hope in cases of Cisplatin resistant tumours.
  33. (1992). Intracavitary administration of interleukin-2 as palliative therapy for neoplastic eVusions.
  34. (1999). Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma: a Phase II study.
  35. (1995). Intrapleural administration of interleukin-2 in pleural mesothelioma: a phase I-II study.
  36. (1997). Intrapleural administration of recombinant interleukin-2 in non-small cell lung cancer with neoplastic pleural eVusion.
  37. (2005). Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors.
  38. (1993). Intratumoral interleukin-2 immunotherapy: activation of tumor-inWltrating and splenic lymphocytes in vivo.
  39. (1991). Intratumoral low-dose interleukin-2 induces rejection of distant solid tumour.
  40. (1998). Intravesical IL-2 to treat T1 papillary carcinoma : regression of marker lesions in 8 out of 10 patients.
  41. (1998). Letter to the Editor. Urology 160:1808
  42. (1987). Local and systemic eVects during interleukin-2 therapy of mouse mammary tumors.
  43. (1989). Local continuous high dose interleukin 2: a new therapeutic model for the treatment of advanced bladder carcinoma.
  44. (1989). Local IL-2 therapy in bovine ocular squamous cell carcinoma. A pilot study.
  45. (1995). Local immunotherapy of superWcial bladder cancer by intravesical instillation of recombinant interleukin 2. Eur Urol
  46. (2005). Local interleukin-2 and interleukin-12 therapy of bovine ocular squamous cell carcinomas.
  47. (2005). Local interleukin2 therapy is therapeutically more eVective against cancer when injected intratumourally.
  48. (1999). Local intratumor immunotherapy of prostate cancer with interleukin-2 reduces tumor growth.
  49. (1999). Local low-dose IL-2 therapy of tumours in companion animals.
  50. (1997). Local low-dose interleukin-2 induces systemic immunity when combined with radiotherapy of cancer. A pre-clinical study.
  51. (1986). Local treatment with human recombinant IL-2 inhibits growth of MC-induced sarcomas in syngeneic mice. Folia Biol (Praha)
  52. (2005). Locoregional IL-2 low dose application for gastrointestinal tumors.
  53. (1993). Low doses of interleukin-2 can cure large bovine ocular squamous cell carcinoma.
  54. (1990). Maintenance and cure of the L5178Y murine tumordormant state by interleukin-2: in vivo and in vitro eVects.
  55. (1982). Microvascular pressures in DMBA-induced rat mammary tumors.
  56. (2004). Modulation of CD3-zeta as a marker of clinical response to IL-2 therapy in ovarian cancer patients. Gynecol Oncol 94:54–60
  57. (2001). Neoadiuvant treatment with intravesical Interleukin-2 for recurrent superWcial transitional bladder carcinoma Ta-T1/G1–2.
  58. (1985). Observations on the systemic administration of autologous lymphokine activated killer cells and recombinant IL-2 to patients with metastatic cancer.
  59. (2001). Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural eVusion: results of a phase II study on 31 consecutive patients. Lung Cancer 31:303–
  60. (1994). PEG-IL-2 therapy of advanced cancer in the guinea pig. Impact of the primary tumor and beneWcial eVect of cyclophosphamide.
  61. (1995). Peptide-induced anergy in allergen-speciWc human Th2 cells results in lack of cytokine production and B cell help for IgE synthesis. Reversal by IL-2, not by IL-4 or IL-13.
  62. (1991). Peri-tumor interleukin-2 causes systemic therapeutic eVect via interferon-gamma induction.
  63. (2000). Perilesional IL-2 treatment of a VX2 head and neck cancer model can induce a systemic anti-tumour activity.
  64. (2007). Phase I/II study of topical imiquinod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma.
  65. (1994). Phase Ib trial of the eVect of peritumoral and intranodal injections of interleukin-2 in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial.
  66. (2003). Phase II trial of intralesional therapy with interleukin-2 in soft tissue melanoma metastases.
  67. (2001). Phase II trial of systemic recombinant interleukin-2 in the treatment of refractory nasopharyngeal carcinoma.
  68. (1992). Polyethylene-glycol-modiWed interleukin-2 is superior to interleukin-2 in locoregional immunotherapy of established guinea pig tumours.
  69. (2007). Prospective review in patients with pulmonary metastases of renal cell carcinoma receiving inhaled recombinant interleukin-2. Anticancer Drugs 18:291–296
  70. (1995). Reevaluation of the superiority of polyethylene glycol modiWed Interleukin-2 over regular recombinant IL-2.
  71. (1985). Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin-2.
  72. (2004). Regulatory T cell suppression and anergy are diVerentially regulated by proinXammatory cytokines produced by TLRactivated dendritic cells.
  73. Rekvig OP (2004) Interleukin-2, but not interleukin-15, is required to terminate experimentally induced clonal T-cell anergy.
  74. Restifo NP (2005) CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2.
  75. (1964). Squamous-cell carcinoma of the vulva in cattle
  76. (1995). Studies on evaluating the antitimour acticity and toxicity of interleukin-15, a new T cell growth factor: comparison with interleukin-2.
  77. (1986). Successful immunotherapy of mouse melanoma and sarcoma with recombinant interleukin-2 and cyclophosphamide.
  78. (2003). T cell anergy and costimulation.
  79. (2002). Testing therapeutic potency of anticancer drugs in animal studies: a commentary. Regul Toxicol Pharmacol 35:266–272
  80. (1987). The anti-tumour eYcacy of human recombinant interleukin 2. Correlation between sensitivity of tumours to the cytolytic eVect of LAK cells in vitro and their susceptibility to interleukin 2 immunotherapy in vivo.
  81. (2002). The mechanism of regression of solid SL2 lymphosarcoma after local IL-2 therapy.
  82. (1996). The success of locoregional low-dose recombinant interleukin-2 (rIL-2) therapy in tumor-bearing mice is dependent on the time of rIL-2 administration.
  83. (1994). The TH, de Leij L
  84. (2003). Therapeutic eVect of a single dose of IL-2 on transplanted murine breast cancer.
  85. (1995). Therapy of bovine ocular squamous cell carcinoma with local doses of Interleukin-2 : 67% complete regressions after 20 months of follow-up.
  86. (1998). Thymus requirement and antigen dependency in the “Infectious” tolerance pathway in transplant recipients.
  87. (1995). Tissue distribution and tumor localisation of eVector cells in adoptive immunotherapy of cancer.
  88. (1985). Toulcova A
  89. (1991). Treatment of murine transitional cell carcinoma with intralesional interleukin-2 and murine interferon gamma.
  90. (2006). Treatment of ocular squamous cell carcinomas in cattle using interleukin-2. Vet Rec 159:668–672
  91. (2005). Treatment of stage III-IV nasopharyngeal carcinomas by external beam irradiation and local low doses of IL-2.
  92. (1996). Treatment of superWcial bladder cancer with intravesical perfusion of rIL-2: a follow-up study.
  93. (1993). Treatment of superWcial transitional cell carcinoma of the bladder with recombinant interleukin-2 (rIL-2) (CETUS).
  94. (1999). Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody.
  95. (1984). Tumour regression after intralesional injection of interleukin-2 (IL-2) in bladder cancer. Preliminary report.
  96. (1991). Tumour regression by IL-2 mediated stagnation of blood Xow.
  97. (1984). Vascular endothelium as vulnerable element in tumours.
  98. (1997). Vascular leak syndrome: a side eVect of immunotherapy.